Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination With Cytarabine Compared to Daunorubicin in Combination With Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- The ACCEDE Study

NCT00715637 is registered in ClinicalTrials.gov with Antisoma Research as lead sponsor.

NCT NCT00715637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00715637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination With Cytarabine Compared to Daunorubicin in Combination With Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- The ACCEDE Study
Lead sponsor
Antisoma Research
Phase
Phase 3
Overall status
Unknown status
Start date
June 30, 2007
Completion date
Not reported
Enrollment
420 (estimated)
Sites
158

Conditions

As the registry lists them; a condition with its own page is linked.

secondary acute myeloid leukemia (secondary aml, saml)